My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 130

    1.

    Case reports of heart failure after therapy with a tumor necrosis factor antagonist.

    Kwon HJ, Coté TR, Cuffe MS, Kramer JM, Braun MM.

    Ann Intern Med. 2003 May 20;138(10):807-11. Review.PMID: 12755552 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Summaries for patients. Tumor necrosis factor antagonists and heart failure.

    [No authors listed]

    Ann Intern Med. 2003 May 20;138(10):I48. No abstract available. PMID: 12755581 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists.

    Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM.

    Rheumatology (Oxford). 2007 Nov;46(11):1688-93. Epub 2007 Oct 15.PMID: 17938138 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series.

    Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P.

    J Rheumatol. 2007 Feb;34(2):380-5. Epub 2006 Oct 1.PMID: 17013997 [PubMed - indexed for MEDLINE]Related articles

    5.

    Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

    Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.

    Arthritis Rheum. 2008 Mar;58(3):667-77.PMID: 18311816 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.

    Wolfe F, Michaud K.

    Am J Med. 2004 Mar 1;116(5):305-11.PMID: 14984815 [PubMed - indexed for MEDLINE]Related articles

    7.

    The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists.

    Cole J, Busti A, Kazi S.

    Rheumatol Int. 2007 Feb;27(4):369-73. Epub 2006 Oct 7.PMID: 17028862 [PubMed - indexed for MEDLINE]Related articles

    8.

    Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

    Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM.

    Arthritis Rheum. 2002 Dec;46(12):3151-8.PMID: 12483718 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.

    Mohan N, Edwards ET, Cupps TR, Slifman N, Lee JH, Siegel JN, Braun MM.

    J Rheumatol. 2004 Oct;31(10):1955-8.PMID: 15468359 [PubMed - indexed for MEDLINE]Related articles

    10.

    Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.

    Wendling D, Balblanc JC, Briançon D, Brousse A, Lohse A, Deprez P, Humbert P, Aubin F.

    Joint Bone Spine. 2008 May;75(3):315-8. Epub 2008 Feb 11.PMID: 18329935 [PubMed - indexed for MEDLINE]Related articles

    11.

    Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.

    Gomez-Reino JJ, Carmona L; BIOBADASER Group.

    Arthritis Res Ther. 2006;8(1):R29. Epub 2006 Jan 6.PMID: 16507128 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    [Dilated cardiomyopathy as a side effect of treatment with infliximab]

    Leetmaa TH, Markenvard JD.

    Ugeskr Laeger. 2005 Sep 26;167(39):3699-701. Danish. PMID: 16219221 [PubMed - indexed for MEDLINE]Related articles

    13.

    Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?

    Ang HT, Helfgott S.

    J Rheumatol. 2003 Nov;30(11):2315-8.PMID: 14677170 [PubMed - indexed for MEDLINE]Related articles

    14.

    Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.

    Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM.

    Clin Infect Dis. 2004 Aug 1;39(3):295-9. Epub 2004 Jul 16.PMID: 15306993 [PubMed - indexed for MEDLINE]Related articles

    15.

    Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

    Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group.

    Arthritis Rheum. 2003 Aug;48(8):2122-7.PMID: 12905464 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

    Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA.

    Medicine (Baltimore). 2007 Jul;86(4):242-51.PMID: 17632266 [PubMed - indexed for MEDLINE]Related articles

    17.

    Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.

    Fleishmann RM.

    Clin Exp Rheumatol. 2002 Sep-Oct;20(5 Suppl 27):S35-41. Review.PMID: 14989428 [PubMed - indexed for MEDLINE]Related articles

    18.

    Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM.

    N Engl J Med. 2001 Oct 11;345(15):1098-104.PMID: 11596589 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.

    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N.

    Arthritis Rheum. 2005 Jul;52(7):1986-92.PMID: 15986370 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

    Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register.

    Arthritis Rheum. 2007 Jan;56(1):13-20.PMID: 17195186 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity